December 22, 2017 09:32 AM EST

Novartis' Tafinlar/Mekinist combo for melanoma gets priority review designation; Fosun Pharma backs joint venture's $190M share issue

Amber Tong

→ Last October Novartis $NVS won a breakthrough designation for a combination of Tafinlar and Mekinist for its work involving patients with stage III melanoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis' Tafinlar/Mekinist combo for melanoma gets priority review designation; Fosun Pharma backs joint venture's $190M share issue

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

FDA OKs the first-ever self-administered vaccine, for flu

The drug lobby's lawsuit against the IRA finds a sign of life after appeals court ruling

Biotech VC firm outlines plans for $100M fund

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

No­var­tis' Tafin­lar/Mekin­ist com­bo for melanoma gets pri­or­i­ty re­view des­ig­na­tion; Fo­s­un Phar­ma backs joint ven­ture's $190M share is­sue

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis' Tafinlar/Mekinist combo for melanoma gets priority review designation; Fosun Pharma backs joint venture's $190M share issue